Review

Research progress of imaging markers for identifying and predicting the progression of age-related macular degeneration

  • Yi-yang SHU ,
  • Si-qi ZHANG ,
  • Hai-yun LIU
Expand
  • Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; National Clinical Research Center for Eye Diseases; Shanghai Key Laboratory of Ocular Fundus Diseases; Shanghai Engineering Center for Visual Science and Photomedicine; Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai 200080, China
LIU Hai-yun, E-mail: drliuhaiyun@126.com.

Received date: 2020-11-24

  Online published: 2021-08-24

Supported by

National Key R&D Program of China(2016YFC0904800);National Science and Technology Major Project of China(2017ZX09304010)

Abstract

With the increase in the number of age-related macular degeneration (AMD) patients, imaging markers with indicative value have been screened and applied to the initial screening of AMD, disease warning, recurrence reminder and treatment guidance to contribute to the early diagnosis and accurate treatment for AMD patients. In clinical practice, colour fundus photography, optical coherence tomography (OCT), optical coherence tomography angiography (OCTA) and fundus angiography are mostly used for image recognition and analysis. This article reviews the imaging markers for identifying and predicting the progression of early-, middle- and late-stage AMD, as well as predicting the recurrence and prognosis of AMD, aiming to provide a theoretical basis and treatment guidance for clinical judgment.

Cite this article

Yi-yang SHU , Si-qi ZHANG , Hai-yun LIU . Research progress of imaging markers for identifying and predicting the progression of age-related macular degeneration[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(9) : 1240 -1245 . DOI: 10.3969/j.issn.1674-8115.2021.09.016

References

1 Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis[J]. Lancet Glob Health, 2014, 2(2): e106-e116.
2 Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern?[J]. Ophthalmology, 2020, 127(1): P1-P65.
3 Murray IJ, Makridaki M, van der Veen RL, et al. Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study[J]. Invest Ophthalmol Vis Sci, 2013, 54(3): 1781-1788.
4 王诗惠, 戴乐舒, 宋剑涛. 年龄相关性黄斑变性玻璃膜疣的研究概况[J]. 国际眼科纵览, 2018, 42(3): 145-148.
5 Abdelfattah NS, Zhang HY, Boyer DS, et al. Drusen volume as a predictor of disease progression in patients with late age-related macular degeneration in the fellow eye[J]. Invest Ophthalmol Vis Sci, 2016, 57(4): 1839-1846.
6 Folgar FA, Yuan EL, Sevilla MB, et al. Drusen volume and retinal pigment epithelium abnormal thinning volume predict 2-year progression of age-related macular degeneration[J]. Ophthalmology, 2016, 123(1): 39-50.e1.
7 de Sisternes L, Simon N, Tibshirani R, et al. Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression[J]. Invest Ophthalmol Vis Sci, 2014, 55(11): 7093-7103.
8 Schlanitz FG, Baumann B, Kundi M, et al. Drusen volume development over time and its relevance to the course of age-related macular degeneration[J]. Br J Ophthalmol, 2017, 101(2): 198-203.
9 Bogunovic H, Montuoro A, Baratsits M, et al. Machine learning of the progression of intermediate age-related macular degeneration based on OCT imaging[J]. Invest Ophthalmol Vis Sci, 2017, 58(6): BIO141-BIO150.
10 Veerappan M, El-Hage-Sleiman AM, Tai V, et al. Optical coherence tomography reflective drusen substructures predict progression to geographic atrophy in age-related macular degeneration[J]. Ophthalmology, 2016, 123(12): 2554-2570.
11 Ouyang Y, Heussen FM, Hariri A, et al. Optical coherence tomography-based observation of the natural history of drusenoid lesion in eyes with dry age-related macular degeneration[J]. Ophthalmology, 2013, 120(12): 2656-2665.
12 Lei JQ, Balasubramanian S, Abdelfattah NS, et al. Proposal of a simple optical coherence tomography-based scoring system for progression of age-related macular degeneration[J]. Graefes Arch Clin Exp Ophthalmol, 2017, 255(8): 1551-1558.
13 Christenbury JG, Folgar FA, O′Connell RV, et al. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci[J]. Ophthalmology, 2013, 120(5): 1038-1045.
14 Sleiman K, Veerappan M, Winter KP, et al. Optical coherence tomography predictors of risk for progression to non-neovascular atrophic age-related macular degeneration[J]. Ophthalmology, 2017, 124(12): 1764-1777.
15 Nassisi M, Fan WY, Shi Y, et al. Quantity of intraretinal hyperreflective foci in patients with intermediate age-related macular degeneration correlates with 1-year progression[J]. Invest Ophthalmol Vis Sci, 2018, 59(8): 3431-3439.
16 Schmidt-Erfurth U, Waldstein SM, Klimscha S, et al. Prediction of individual disease conversion in early AMD using artificial intelligence[J]. Invest Ophthalmol Vis Sci, 2018, 59(8): 3199-3208.
17 Fragiotta S, Rossi T, Cutini A, et al. Predictive factors for development of neovascular age-related macular degeneration: a spectral-domain optical coherence tomography study[J]. Retina, 2018, 38(2): 245-252.
18 Arnold JJ, Sarks SH, Killingsworth MC, et al. Reticular pseudodrusen. A risk factor in age-related maculopathy[J]. Retina, 1995, 15(3): 183-191.
19 Zweifel SA, Imamura Y, Spaide TC, et al. Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration[J]. Ophthalmology, 2010, 117(9): 1775-1781.
20 Finger RP, Wu Z, Luu CD, et al. Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization[J]. Ophthalmology, 2014, 121(6): 1252-1256.
21 Finger RP, Chong E, McGuinness MB, et al. Reticular pseudodrusen and their association with age-related macular degeneration: the Melbourne collaborative cohort study[J]. Ophthalmology, 2016, 123(3): 599-608.
22 Zhou Q, Daniel E, Maguire MG, et al. Pseudodrusen and incidence of late age-related macular degeneration in fellow eyes in the comparison of age-related macular degeneration treatments trials[J]. Ophthalmology, 2016, 123(7): 1530-1540.
23 Farsiu S, Chiu SJ, O′Connell RV, et al. Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography[J]. Ophthalmology, 2014, 121(1): 162-172.
24 Marsiglia M, Boddu S, Bearelly S, et al. Association between geographic atrophy progression and reticular pseudodrusen in eyes with dry age-related macular degeneration[J]. Invest Ophthalmol Vis Sci, 2013, 54(12): 7362-7369.
25 Niu SJ, de Sisternes L, Chen Q, et al. Fully automated prediction of geographic atrophy growth using quantitative spectral-domain optical coherence tomography biomarkers[J]. Ophthalmology, 2016, 123(8): 1737-1750.
26 Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration?[J]. Retina, 2010, 30(9): 1333-1349.
27 Iafe NA, Phasukkijwatana N, Sarraf D. Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration[J]. Dev Ophthalmol, 2016, 56: 45-51.
28 Kuehlewein L, Bansal M, Lenis TL, et al. Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration[J]. Am J Ophthalmol, 2015, 160(4): 739-748.e2.
29 El Ameen A, Cohen SY, Semoun O, et al. Type 2 neovascularization secondary to age-related macular degeneration imaged by optical coherence tomography angiography[J]. Retina, 2015, 35(11): 2212-2218.
30 Farecki ML, Gutfleisch M, Faatz H, et al. Characteristics of type 1 and 2 CNV in exudative AMD in OCT-angiography[J]. Graefes Arch Clin Exp Ophthalmol, 2017, 255(5): 913-921.
31 Nagiel A, Sarraf D, Sadda SR, et al. Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography[J]. Retina, 2015, 35(4): 638-647.
32 Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group[J]. Ophthalmology, 2020, 127(5): 616-636.
33 De Salvo G, Vaz-Pereira S, Keane PA, et al. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2014, 158(6): 1228-1238.e1.
34 Liu R, Li JQ, Li ZJ, et al. Distinguishing polypoidal choroidal vasculopathy from typical neovascular age-related macular degeneration based on spectral domain optical coherence tomography[J]. Retina, 2016, 36(4): 778-786.
35 Daniel E, Toth CA, Grunwald JE, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials[J]. Ophthalmology, 2014, 121(3): 656-666.
36 Willoughby AS, Ying GS, Toth CA, et al. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials[J]. Ophthalmology, 2015, 122(9): 1846-1853.e5.
37 Casalino G, Stevenson MR, Bandello F, et al. Tomographic biomarkers predicting progression to fibrosis in treated neovascular age-related macular degeneration: a multimodal imaging study[J]. Ophthalmol Retina, 2018, 2(5): 451-461.
38 Coscas GJ, Lupidi M, Coscas F, et al. Optical coherence tomography angiography versus traditional multimodal imaging in assessing the activity of exudative age-related macular degeneration: a new diagnostic challenge[J]. Retina, 2015, 35(11): 2219-2228.
39 Schmidt-Erfurth U, Waldstein SM, Deak GG, et al. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration[J]. Ophthalmology, 2015, 122(4): 822-832.
40 von der Burchard C, Treumer F, Ehlken C, et al. Retinal volume change is a reliable OCT biomarker for disease activity in neovascular AMD[J]. Graefes Arch Clin Exp Ophthalmol, 2018, 256(9): 1623-1629.
41 Forte R, Coscas F, Serra R, et al. Long-term follow-up of quiescent choroidal neovascularisation associated with age-related macular degeneration or pachychoroid disease[J]. Br J Ophthalmol, 2020, 104(8): 1057-1063.
42 Al-Sheikh M, Iafe NA, Phasukkijwatana N, et al. Biomarkers of neovascular activity in age-related macular degeneration using optical coherence tomography angiography[J]. Retina, 2018, 38(2): 220-230.
43 Bae K, Kim HJ, Shin YK, et al. Predictors of neovascular activity during neovascular age-related macular degeneration treatment based on optical coherence tomography angiography[J]. Sci Rep, 2019, 9(1): 19240.
44 Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results[J]. Ophthalmology, 2020, 127(4S): S135-S145.
45 Waldstein SM, Wright J, Warburton J, et al. Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD[J]. Ophthalmology, 2016, 123(1): 60-69.
46 Cuilla TA, Ying GS, Maguire MG, et al. Influence of the vitreomacular interface on treatment outcomes in the comparison of age-related macular degeneration treatments trials[J]. Ophthalmology, 2015, 122(6): 1203-1211.
47 Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols[J]. Acta Ophthalmol, 2018, 96(2): 120-133.
48 Kang HM, Kwon HJ, Yi JH, et al. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration[J]. Am J Ophthalmol, 2014, 157(5): 1013-1021.
49 Midena E, Vujosevic S, Convento E, et al. Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration[J]. Br J Ophthalmol, 2007, 91(11): 1499-1503.
50 Paques M, Meimon S, Rossant F, et al. Adaptive optics ophthalmoscopy: application to age-related macular degeneration and vascular diseases[J]. Prog Retin Eye Res, 2018, 66: 1-16.
51 Schlegl T, Waldstein SM, Bogunovic H, et al. Fully automated detection and quantification of macular fluid in OCT using deep learning[J]. Ophthalmology, 2018, 125(4): 549-558.
52 Saha S, Nassisi M, Wang M, et al. Automated detection and classification of early AMD biomarkers using deep learning[J]. Sci Rep, 2019, 9(1): 10990.
Outlines

/